drugset / Trial / NCT01302340
Delta-THC in Behavioral Disturbances in Dementia
RandomizedCrossoverQuadruple-blindTreatment
Summary
Dementia is a common chronic condition, with predicted increasing prevalence. Nearly all patients with dementia will experience neuropsychiatric symptoms (NPS). This causes significant burden for the individual patients and their caregivers. Current treatment has only modest efficacy and important side-effects. Formulations with Δ9-tetrahydrocannabinol (THC), the psycho-active compound of cannabis, are currently being registered for spasms in multiple sclerosis and other diseases, and may have beneficial effects on NPS.
Timeline
- Start
- 2011-09
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dronabinol | Other / unclassified | 0.75 mg | Oral |
| Comparator | Dronabinol | Other / unclassified | 1.5 mg | Oral |